Docket No.: 02420/100M761-US1

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Withdrawn) A method for promoting outgrowth of a mammalian neuron comprising contacting said neuron with the peptide of claim 6.

- 2. (Canceled)
- 3. (Canceled)
- 4. (Canceled)
- 5. (Canceled)
- 6. (Currently Amended) An isolated peptide derived from the ankyrin binding domain of an L1-CAM family member protein, wherein said peptide (i) does not contain transmembrane and extracellular portions of the L1-CAM family member protein, (ii) comprisesing thean amino acid sequence of QFNEDGSFIGQF (SEQ ID NO: 2), and , wherein said peptide (iii) promotes neurite outgrowth.
- 7. (Currently Amended) The peptide of claim 6 comprising thean amino acid sequence of QFNEDGSFIGQF (SEQ ID NO: 2) linked to thean amino acid sequence of RQIKIWFQNRRMKWKK (SEQ ID NO: 6), wherein said sequences are linked by a disulfide bond.
 - 8. (Canceled)
 - 9. (Canceled)
 - 10. (Canceled)
 - 11. (Canceled)

- 12. (Canceled)
- 13. (Canceled)
- 14. (Canceled)
- 15. (Canceled)
- 16. (Canceled)
- 17. (Canceled)
- 18. (Previously Presented) A pharmaceutical composition comprising the peptide of claim 6 and a pharmaceutically acceptable carrier.
- 19. (Currently Amended) An isolated peptide consisting essentially of (i) the ankyrin binding domain of an L1-CAM family member protein or a fragment of such ankyrin binding domain, wherein the carboxy-terminal tyrosine is substituted with phenylalanine and which comprises thean amino acid sequence of QFNEDGSFIGQF (SEQ ID NO: 2) and (ii) optionally, a targeting sequence which allows translocation of the peptide across the plasma membrane and into the cytoplasm of cells, wherein said peptide promotes neurite outgrowth.
- 20. (Currently Amended) <u>An isolated The-peptide of claim 19</u> consisting of <u>thean</u> amino acid sequence of OFNEDGSFIGOF (SEO ID NO: 2).
- 21. (Previously Presented) A pharmaceutical composition comprising the peptide of claim 19 and a pharmaceutically acceptable carrier.
- 22. (Previously Presented) The peptide of claim 6 which comprises a targeting sequence which allows translocation of the peptide across the plasma membrane and into the cytoplasm of cells.
- 23. (Currently Amended) The peptide of claim 22, wherein the targeting sequence comprises thean amino acid sequence of RQIKIWFQNRRMKWKK (SEQ ID NO: 6).

Application No. 10/561,015 Response After Final Office Action of June 23, 2009 Docket No.: 02420/100M761-US1

- 24. (Currently Amended) <u>An isolated The peptide of claim 23</u> consisting of <u>thean</u> amino acid sequence <u>of RQIKIWFQNRRMKWKKQFNEDGSFIGQF</u> (SEQ ID NO: 3).
 - 25. (Canceled)